Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry [5] Core Viewpoints - Short-term fluctuations do not change the long-term growth trajectory of the innovative drug sector. Despite recent market volatility, the underlying logic for medium to long-term growth remains intact, driven by globalization, technological breakthroughs, and industry upgrades [8][12] - The focus has shifted from "can we go global" to "what progress has been made after going global," emphasizing the importance of overseas clinical deployment and milestone achievements for innovative drugs [13][14] - Breakthroughs in frontier technologies, particularly in small nucleic acids and CAR-T therapies, position Chinese companies to become core global assets [18][20] - The commercialization of innovative drugs is expected to lead to a profitability inflection point, with key companies entering a positive cycle of product volume growth and reinvestment in R&D [22] Summary by Sections 1. Short-term Fluctuations, Long-term Growth - The innovative drug sector has experienced significant volatility due to concentrated expectations and emotions, but the long-term growth trend remains unchanged [8][12] - The valuation of leading companies has reached reasonable levels, suggesting potential investment opportunities as market sentiment stabilizes [12] 1.1 Focus on Globalization Progress - The emphasis has shifted to the progress of products in overseas clinical trials, with a focus on key data readouts and milestone achievements [13][14] - Domestic bispecific antibodies are accelerating their global clinical trials, becoming core trading assets in the context of expiring patents for PD-(L)1 products [13] 1.2 Breakthroughs in Frontier Technologies - Chinese companies are leading in small nucleic acids and CAR-T therapies, with significant advancements in delivery technologies expanding treatment options beyond rare diseases [18] - In vivo CAR-T therapies have shown preliminary clinical effectiveness, with a growing number of transactions indicating a shift towards mainstream adoption [20] 1.3 Commercialization Driving Profitability - Leading innovative drug companies are entering a cycle of product volume growth that supports R&D reinvestment, with expectations for exceeding market performance in 2023 [22] - The upcoming earnings period in March-April 2026 is seen as a critical validation point for the sector [22] 2. Global New Drugs: Highlights in Autoimmunity and Oncology - The report highlights the approval of the world's first PD-L1/TGF-β bispecific antibody, showcasing the R&D capabilities of domestic companies [26][27] - The successful launch of innovative drugs in critical therapeutic areas reflects the growing strength of domestic pharmaceutical companies in addressing unmet medical needs [26][27]

Investment Rating - The report maintains a "Positive" outlook for the innovative pharmaceutical sector in China [5]. Core Viewpoints - Short-term fluctuations do not alter long-term growth prospects. The innovative drug sector has experienced increased volatility due to external factors, but the underlying logic for medium to long-term growth remains intact. The report suggests focusing on investment opportunities once market volatility stabilizes [8][12]. - Key investment themes include "outbound execution," "breakthroughs in cutting-edge technologies," and "profitability inflection points" [3][8]. Summary by Sections 1. Short-term Fluctuations, Long-term Growth - The innovative drug sector has been experiencing significant fluctuations since the beginning of the year, driven by investor sentiment and market adjustments. However, the long-term trends of globalization, technological breakthroughs, and industrial upgrades remain unchanged [12]. - The focus has shifted from "can we go abroad" to "what progress is made after going abroad," emphasizing the importance of clinical deployment and milestone achievements in overseas markets [13][14]. 1.1 Outbound Execution Becomes Key - The report highlights that the focus on outbound strategies has transitioned to the progress of products in overseas clinical trials. The performance of domestic dual antibodies in global clinical trials is becoming a focal point for the industry [13][14]. 1.2 Breakthroughs in Cutting-edge Technologies - Chinese companies are making significant advancements in small nucleic acids and cell therapies, positioning themselves as core assets in global transactions. The report notes that small nucleic acids are expanding beyond rare diseases and metabolic disorders, with breakthroughs in delivery technologies [18][19]. - In vivo CAR-T therapies are showing promising initial clinical results, with a growing number of transactions in this area, indicating a shift towards more mainstream applications [20][21]. 1.3 Commercialization Drives Profitability Inflection Points - Leading innovative pharmaceutical companies are entering a positive cycle of product commercialization and reinvestment in R&D. The report anticipates that 2026 will be a critical year for profitability, with key performance periods in March and April serving as important validation points [22][23]. 2. Global New Drugs: Highlights in Autoimmunity and Oncology - The report discusses the approval of the world's first PD-L1/TGF-β dual antibody, highlighting the strength of domestic R&D capabilities. This drug, approved for advanced gastric cancer, showcases the potential for domestic companies to achieve significant milestones in drug development [26][27].

Core Viewpoint - The Chinese government is accelerating the cultivation of leading technology enterprises and prioritizing the support of key common technology needs of enterprises as a significant direction for national science and technology plans [1] Group 1: Technology Development and Innovation - The large-scale application of new scenarios relies on the drive of cutting-edge technologies, and breakthroughs in these technologies will continuously generate new fields and application scenarios [1] - The Ministry of Science and Technology aims to strengthen the tackling of key core technologies and promote decisive breakthroughs in key areas through a coordinated national strategic technology force [1] Group 2: Innovation Mechanism - A rapid iterative innovation mechanism will be formed, characterized by "demand-driven—technology breakthrough—scenario verification—industrial application" [1] - The government will promote the aggregation of innovation resources towards enterprises and support them in leading the establishment of innovation consortia, taking on more national technology tackling tasks [1] Group 3: Capital and Investment - There will be greater autonomy for scientific personnel in the distribution of benefits from the transformation of scientific achievements, facilitating the efficient conversion of major cutting-edge technological results [1] - Policies will be improved to guide long-term capital to invest early, in small amounts, for the long term, and in hard technology, with increased efforts to attract social capital to participate in technology entrepreneurship investment [1]